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Abstract. The utilization of decision support systems, in the point of care, to alert 
drug-drug interactions has been shown to improve quality of care. Still, the use of 
these systems has not been as expected, it is believed, because of the difficulties in 
their knowledge databases; errors in the generation of the alerts and the lack of a 
suitable design. This study expands on the development of alerts using 
participatory design techniques based on user centered design process. This work 
was undertaken in three stages (inquiry, participatory design and usability testing) 
it showed that the use of these techniques improves satisfaction, effectiveness and 
efficiency in an alert system for drug-drug interactions, a fact that was evident in 
specific situations such as the decrease of errors to meet the specified task, the 
time, the workload optimization and users overall satisfaction in the system. 
Keywords. Decision support systems, Drug-drug interaction, User centered design, 
Usability, Human computer interaction. 
Introduction 
The clinical decision support systems are a useful tool for improving the quality of care 
(1), even more in the field of electronic prescribing and especially in the domain of 
drug-drug interaction (DDI) alerts (2-4). Although this advantage is known, it is not 
uncommon to find reports indicating a high rate of override of these alerts (5), citing 
reasons ranging from inadequate construction of the knowledge database (6) and the 
lack of clinical significance of the alerts (7), and the poor design of the human-
computer interfaces (3), therefore any action aimed at improving these aspects would 
result in improving the rate of the acceptance of this alerts and the patient safety (7). 
The Hospital Italiano of Buenos Aires (HIBA) developed and implemented a clinical 
information system with a DDI alert system (8), but the override rate of the delivered 
alerts was high. Following literature recommendations that stressed the importance of 
user centric techniques, the decision was made to redesign DDI alert system 
components. At first we worked on a primary phase of purging and categorizing of the 
knowledge database recommendations (9), to then move forward in redesigning the 
human computer interaction of the alerts. This work aims to describe the participatory 
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design phase for the development of a new DDI alert based in a user centered design 
process. 
1. Methods 
This work took place at HIBA from September 2013 to April 2014.  The HIBA is a 
high complexity university hospital. It has a clinical information system developed "in 
house" that handles the medical and administrative information (10, 11). This system 
supports among other features clinical provider order entry (CPOE) (10). In this 
context, three clinical pharmacologists depurated and optimize the pharmacological 
knowledge database (done in-house, based on international evidence) (12) to serve as a 
substrate for the development of the project. Later a team of 3 physicians specialized in 
medical informatics and two usability experts worked in a user centered design process, 
following the steps of the ISO 9241-210 (13). The project was raised in iterative stages: 
Stage 1: Inquiry: consisted of interviews and contextual observations (14) dealt 
with topics relating to the processes of prescribing drugs in situations where drug 
interactions were presented. From the analysis of these interviews low-fidelity 
prototypes were generated, as a way to confront the ideas that emerged from the 
interviews with the design of DDI alerts interfaces. Participants’ profiles: physicians 
that worked in ambulatory care and inpatient settings and 4 years of experience using 
the system. Semi-structured questionnaire was given to the users to guide them through 
dynamic clinical scenarios that were developed based on real clinical cases (15).  
Stage 2: Participatory Design:  Participatory design stage was conducted using the 
low-fidelity prototypes. Participating physicians guided the development of a new 
prototype, closer to the user feedback. Two cycles of prototyping and testing were 
conducted. The focus was qualitative, seeking the domain saturation. The opinions and 
thoughts of physicians were obtained and recorded using Think Aloud technique (16). 
Profiles were similar as those who were involve in Stage 1. The script used in the test 
was also based on real cases. At this stage, two prototypes were used, the 1st one, made 
in Balsamiq® (17) was printed on paper and showed to users, 2nd one also made in  
Balsamiq® was exported and used in order to reproduce the prescription process as 
closely as possible. Stage 2: Usability Testing: For the usability testing, high fidelity 
prototype were developed in Axure® (18), and presented to a new sample of users.  
This instance was used to measure effectiveness, which was understood from two 
variables, the first referring about if they override the warning or took it into account 
and acted upon and the second was whether they could complete the process of 
prescribing. Efficiency, which measured the progression in the number of clicks and 
the time needed to accomplish the task and satisfaction that was assessed using a SUS - 
system usability scale questionnaire (19). The whole process was iterative, where each 
step is based on a process of prototyping cycles, seeking to reach domain saturation, in 
order to define a final prototype at each stage to proceed to the subsequent step.  
2. Results 
All of the 24 physicians from three different fields (ambulatory care, inpatient critical 
care and inpatient none critical care) took part in the 3 stages we conducted. 
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Stage 1: 6 doctors participated in the first stage; the interviews in this stage were 
the basis for structuring the prototypes (Figure 1). What emerged from these interviews 
is that the IDD is a common concern among physicians. Several participants made 
comments that coincide with those published in the literature, such as the difficulty of 
finding good resources for detecting interactions, poor interface design, high false 
positive rates, and the fatigue this alerts causing. We then took advantage of the views 
expressed by users to create and give structure to the prototypes that would be used in 
the following steps. They also expressed the desirability or necessity for alerts that 
provide information and guidance concerning the conduct to follow. 
 
 
Figure 1. First prototype 
 
Stage 2: Using participatory design techniques, a different sample of physicians 
generated new interfaces to be tested. The results at this stage were analyzed by non-
stringent qualitative techniques, in order to analyze the results and give them some 
structure. The opinions given at this stage were: alerts were generally well received; the 
possibility of taking actions from the same alert was positively assessed as a way of not 
interrupting the workflows and not having to restart the prescription process. Actions 
integrated as operations were received as a great advantage. Negatives comments: 
several options offered in an alert were thought complex. These results were considered 
for the redesign and re-testing until users deemed them appropriate. Perhaps the main 
result of this stage was the realization that the interface should be action-oriented and 
not just information. (Figure 2). 
Stage 3: Effectiveness: of the 24 physicians, 11 ignored the warning (45, 8%) and 
13 (54.2 %) took action. The other measure of effectiveness was whether the 
physicians could finish the prescription process, in which the following results were 
evident: 13 (54.17 %) physicians completed the task without difficulty, 10 (41.67 %) 
completed the activity with questions or mild errors, and 1 (4.17%) completed the task 
with serious errors. There were no instance where the tasks couldn’t be completed. 
Efficiency measured as the amount of clicks is shown in Table 1, Efficiency 
measured as the time used to accomplish the task in Table 2, and Satisfaction assessed 
from a SUS questionnaire in Table 3. 
This in turn gives an average value of 77.90 per participant on a scale of 0-100 
which indicates a value more than adequate, this equals an 83% percentile, which in 
other words means that the acceptance rate the system is above 80 %. 
 
 
Figure 2. Refined prototype 
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Table 1. efficiency (amount of clicks) for stage 
Action Performance Amount of clicks 
 Stage 1 Stage 2 Stage 3 
Prescribing 
process 
Complete the task 68 70 65 
Complete with questions or mild errors 71 68 65 
Complete with serious errors - - - 
Follow the 
recommended 
action 
Complete the task 54 60 50 
Complete with questions or mild errors 52 75 70 
Complete with serious errors - - - 
Prescription 
cancelled 
Complete the task 13 10 8 
Complete with questions or mild errors 76 75 70 
Complete with serious errors - - - 
 
Table 2: efficiency (time) for stage 
Action Stage 1 (seconds) Stage 2 (seconds) Stage 3(seconds) 
Prescribing process 16 18 15 
Follow the recommended action 11 11 10 
Prescription canceled 9 12 10 
 
Table 3: satisfaction with SUS scale score 
By question Score 
I think I would like to use this system when prescribing 3,00 
The system is unnecessarily complex 3,00 
The system is easy to use 2,90 
I would need the assistance of an expert to use the system 3,90 
The diverse possibilities of the system are well integrated 3,60 
There is too much inconsistency in the system 3,40 
I believe that most of the clinicians could use the system without problems 2,00 
The system is very uncomfortable 3,10 
I felt secure using the system 3,10 
I would need a lot of instructions to manage the system 3,10 
3. Discussion 
From the detailed analysis of the metrics considered in the final stages, both the values 
of effectiveness, efficiency and satisfaction improved until the final prototype. 
Regarding satisfaction, values higher than 80% demonstrate the importance of 
involving users in the design of the system. With regard to the acceptance of the 
recommendations, although a percentage above 50 % is generally considered low 
impact, this performance is more than acceptable in this particular topic, where similar 
studies have thrown much higher alert failure rate. Another problem had to do with the 
creation of clinical cases, they refer to rare problems that doctors do not routinely 
handle, which is presented as one of the challenges for the design framework. Future 
lines: final functional prototype testing: the final stage will be held using the final 
prototype; laboratory testing will be performed from cases generated from the actual 
incidence based on the frequency of cases recovered in previous analysis. 
Limitations: this study was conducted at a single center, so the processes to 
incorporate external validation should be done. Furthermore, the correlation between 
the clinical case and physician specialty was not always as desired, some physicians 
may face situations not commons to their practice, so their actions are not taken with a 
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strong knowledge of the field, but rather by the influence  generated  by the alert  that 
leads to select "suspend" rather than doing harm. 
4. Conclusion 
The incorporation of new participatory design techniques for the development of 
support tools for DDI was a positive experience because it enabled the development 
team to access a large number of errors and valid considerations, which could be 
resolved and improved before passage development 
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